Pfizer vax safe with cancer immunotherapy: study
But long-term C0VID-19 vaccine safety and efficacy in patients on checkpoint inhibitors are yet to be determined, researchers say
A study from Israel supports the short-term safety of the Pfizer-BioNTech mRNA COVID-19 vaccine in patients with cancer being treated with immune checkpoint inhibitors.
The researchers report on 134 adults with cancer receiving immune checkpoint-inhibitor therapy alone (87%) or in combination with chemotherapy (13%) who have received two doses of the vaccine.
